The PurpleLab®
August 2022
News
Higher SARS-COV-2 spike antibody levels are associated with reduced risk of subsequent symptomatic and severe COVID-19. Jin, Yue; Yang, Fei; Rank, Christopher; Letovsky, Stanley; Ramge, Peter and Jochum, Simon from Roche Information Solutions, Roche Diagnostics GmbH, Roche Diagnostics Solutions, and Roche Diagnostics International presented a poster during ISPOR 2024. The objective was to assess the…
Articles
Creating a holistic direct to consumer (DTC) and healthcare provider (HCP) marketing strategy from scratch is a demanding task, especially if you don’t have the clinical expertise to precisely identify the consumers or providers you should be targeting. We’re here to give you 5 simple steps to creating a holistic DTC and HCP targeting strategy…
Whitepapers
Unlock the secrets to extending survival in metastatic NSCLC: This study reveals how biomarker testing and targeted therapies are transforming patient outcomes in the real world.
News
The healthcare analytics company partnered with Experian, DeepIntent, InsightsRx, and Comscore to deliver scale, precision, privacy-conscious targeting, and real-time measurement for pharmaceutical advertisers. PurpleLab®, the healthcare analytics company powering evidence-based decisions across life sciences, has announced a series of major partnerships with Experian, DeepIntent, InsightsRx, and Comscore. Together, these collaborations allow advertisers to use data…
News
Partnership introduces smarter, real-time HCP and DTC optimization leveraging PurpleLab®’s data and InsightsRx’s proprietary algorithmic intelligence. InsightsRx, a healthcare media company on a mission to transform real-world data into smarter, outcome-driven marketing, teams up with PurpleLab, a healthcare analytics company on a mission to make healthcare speak a single unified language to drive better outcomes….
News
Pharmaceutical brands and media platforms, including connected TV (CTV), can activate HIPAA-compliant audiences built on real-world clinical and claims data through a new collaboration between PurpleLab® and Experian. Targeting de-identified audiences is essential for engaging the right patients at pivotal moments in their health journey—maximizing ROI while safeguarding privacy and improving outcomes. Overall, prescription drugmakers…
News
Healthcare advertising works best when it’s both precise and efficient. That’s why we’re excited to announce a direct partnership with DeepIntent, bringing our high-quality audiences into the DeepIntent Audience Marketplace. This integration gives marketers faster, easier access to PurpleLab’s audiences, delivering better performance, greater scale, and sharper precision within a seamless workflow. For advertisers, that…
Articles
Biomarker testing guides selection of targeted therapies in non–small cell lung cancer (NSCLC). Despite its clinical importance, the extent of provider variation in biomarker testing practices and its correlation with patient outcomes has not been thoroughly explored.
News
The collaboration extends PurpleLab®’s healthcare audience reach through Comscore’s AI predictive technology. PurpleLab, a healthcare analytics company powering evidence-based decisions across life sciences, is now part of Comscore’s AI-powered Data Partner Network. The initiative enables data providers like PurpleLab to transform ID-based datasets into scalable, privacy-centric audiences using Proximic by Comscore’s proprietary AI predictive…
News
PurpleLab®, a healthcare analytics company specializing in real-world data, announced it has acquired KAID Health, an AI-powered clinical analytics and care management company. The combination brings together PurpleLab’s large-scale structured claims data with KAID Health’s artificial intelligence and natural language processing technology, creating a more complete view of patient journeys across structured and unstructured data…
Articles
Clinical trials are designed to evaluate the safety and efficacy of new therapies or medical devices. During these trials, evidence is gathered to determine if the asset is safe for patients, providing the intended benefit at the appropriate dosage, as well as identifying and minimizing any potential side effects.